T-502 is under clinical development by Inmunotek and currently in Phase III for Allergic Asthma. According to GlobalData, Phase III drugs for Allergic Asthma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how T-502’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
T-502 is under development for the treatment of rhinitis and rhinoconjunctivitis against mite allergy and allergic asthma. Allergen is administered subcutaneously and sublingually as a solution. The drug candidate is a mannosylated mixture of Dermatophagoides pteronyssinus and Dermatophagoides farina allergen extract.
Inmunotek opearates as a pharmaceutical company. It develops, produces and markets products for allergy and other immune-based diseases and manufactures veterinary medicine. It also produces raw materials such as biological products, including fungi, bacteria and mites.
For a complete picture of T-502’s drug-specific PTSR and LoA scores, buy the report here.